Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic …
…, J Kremer, C Zerbini, MH Cardiel… - Arthritis & …, 2013 - Wiley Online Library
Objective The purpose of this 24‐month phase III study was to examine structural preservation
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …
Clinical and biologic effects of anti–interleukin‐10 monoclonal antibody administration in systemic lupus erythematosus
…, E Claret, J Jakez‐Ocampo, MH Cardiel… - … : Official Journal of …, 2000 - Wiley Online Library
Objective To evaluate the safety and clinical efficacy of administering an anti–interleukin‐10
(anti–IL‐10) monoclonal antibody (mAb) to systemic lupus erythematosus (SLE) patients …
(anti–IL‐10) monoclonal antibody (mAb) to systemic lupus erythematosus (SLE) patients …
The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among …
BA Pons-Estel, LJ Catoggio, MH Cardiel, ER Soriano… - Medicine, 2004 - journals.lww.com
Clinical and laboratory manifestations and outcome of systemic lupus erythematosus (SLE)
may vary in different populations. A prospective multinational inception cohort should prove …
may vary in different populations. A prospective multinational inception cohort should prove …
Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort
…, ME Alarcón‐Riquelme, MH Cardiel… - Arthritis & …, 2005 - Wiley Online Library
Objective To determine whether there is familial aggregation of systemic lupus erythematosus
(SLE) and/or other autoimmune diseases in SLE patients and to identify clinical …
(SLE) and/or other autoimmune diseases in SLE patients and to identify clinical …
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
…, M Mosca, MA Petri, T Dörner, MH Cardiel… - The Lancet, 2018 - thelancet.com
Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …
Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology
…, J Zamudio, N Santana, MH Cardiel - The Journal of …, 2011 - jrheum.org
Objective. To estimate the prevalence of musculoskeletal (MSK) disorders and to describe
predicting variables associated with rheumatic diseases in 5 regions of México. Methods. This …
predicting variables associated with rheumatic diseases in 5 regions of México. Methods. This …
[HTML][HTML] Transancestral mapping and genetic load in systemic lupus erythematosus
…, M Bijl, EE Brown, HI Brunner, MH Cardiel… - Nature …, 2017 - nature.com
Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and
ethnic disparities. We report a large transancestral association study of SLE using Immunochip …
ethnic disparities. We report a large transancestral association study of SLE using Immunochip …
Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices.
J Guzman, MH Cardiel, A Arce-Salinas… - The Journal of …, 1992 - europepmc.org
Several clinical indices have been proposed to measure disease activity in patients with
systemic lupus erythematosus. Only a few have been subjected to extensive analysis. We report …
systemic lupus erythematosus. Only a few have been subjected to extensive analysis. We report …
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …
Risk factors associated with depression in patients with type 2 diabetes mellitus
JF Téllez-Zenteno, MH Cardiel - Archives of medical research, 2002 - Elsevier
BACKGROUND: This study was undertaken in order to identify the prevalence and factors
associated with depression in a group of patients with type 2 diabetes mellitus. METHODS: …
associated with depression in a group of patients with type 2 diabetes mellitus. METHODS: …